Clinical trial
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
NCT03633227 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
- Lead sponsor
- Intercept Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- June 22, 2018
- Completion date
- July 9, 2021
- Enrollment
- 22 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.